These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16143538)

  • 1. Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease.
    Miller RM; Kiser GL; Kaysser-Kranich TM; Lockner RJ; Palaniappan C; Federoff HJ
    Neurobiol Dis; 2006 Feb; 21(2):305-13. PubMed ID: 16143538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism.
    Hauser MA; Li YJ; Xu H; Noureddine MA; Shao YS; Gullans SR; Scherzer CR; Jensen RV; McLaurin AC; Gibson JR; Scott BL; Jewett RM; Stenger JE; Schmechel DE; Hulette CM; Vance JM
    Arch Neurol; 2005 Jun; 62(6):917-21. PubMed ID: 15956162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD.
    Miller RM; Kiser GL; Kaysser-Kranich T; Casaceli C; Colla E; Lee MK; Palaniappan C; Federoff HJ
    Exp Neurol; 2007 Mar; 204(1):421-32. PubMed ID: 17254569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the nigrostriatal dopaminergic neurons in mediating the effect of exogenous L-dopa in Parkinson's disease.
    Melamed E
    Mt Sinai J Med; 1988 Jan; 55(1):35-42. PubMed ID: 3279303
    [No Abstract]   [Full Text] [Related]  

  • 6. Differential expression of Fos and Zif268 in the nigrostriatal system after methamphetamine administration in a rat model of Parkinson's disease.
    Ishida Y; Kawai K; Magata Y; Ebihara K; Takeda R; Abe H; Yoshimoto M; Hashiguchi H; Odagiri K; Matsuo H; Nishimori T
    Synapse; 2008 Dec; 62(12):920-6. PubMed ID: 18792992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Degeneration of the centré median-parafascicular complex in Parkinson's disease.
    Henderson JM; Carpenter K; Cartwright H; Halliday GM
    Ann Neurol; 2000 Mar; 47(3):345-52. PubMed ID: 10716254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain.
    Mogi M; Kondo T; Mizuno Y; Nagatsu T
    Neurosci Lett; 2007 Feb; 414(1):94-7. PubMed ID: 17196747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of electroacupuncture scalp point-through-point therapy on the expression of tyrosine hydroxylase and dopamine transporter mRNAs in substantia nigra of Parkinson's disease model rats].
    Wang S; Qi XJ; Han D
    Zhongguo Zhen Jiu; 2009 May; 29(5):391-4. PubMed ID: 19489498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treadmill exercise suppresses nigrostriatal dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson's rats.
    Yoon MC; Shin MS; Kim TS; Kim BK; Ko IG; Sung YH; Kim SE; Lee HH; Kim YP; Kim CJ
    Neurosci Lett; 2007 Aug; 423(1):12-7. PubMed ID: 17644250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dopaminergic nigrostriatal system and Parkinson's disease: molecular events in development, disease, and cell death, and new therapeutic strategies.
    Hodaie M; Neimat JS; Lozano AM
    Neurosurgery; 2007 Jan; 60(1):17-28; discussion 28-30. PubMed ID: 17228250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
    Chu Y; Kordower JH
    Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered gene expression profiles reveal similarities and differences between Parkinson disease and model systems.
    Miller RM; Federoff HJ
    Neuroscientist; 2005 Dec; 11(6):539-49. PubMed ID: 16282595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson's disease.
    Yasuda T; Fukuda-Tani M; Nihira T; Wada K; Hattori N; Mizuno Y; Mochizuki H
    Exp Neurol; 2007 Aug; 206(2):308-17. PubMed ID: 17604022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential gene expression induced by chronic levodopa treatment in the striatum of rats with lesions of the nigrostriatal system.
    Ferrario JE; Taravini IR; Mourlevat S; Stefano A; Delfino MA; Raisman-Vozari R; Murer MG; Ruberg M; Gershanik O
    J Neurochem; 2004 Sep; 90(6):1348-58. PubMed ID: 15341519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of age and gender on cytokine expression in a murine model of Parkinson's disease.
    Ciesielska A; Joniec I; Kurkowska-Jastrzebska I; Przybyłkowski A; Gromadzka G; Członkowska A; Członkowski A
    Neuroimmunomodulation; 2007; 14(5):255-65. PubMed ID: 18196934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain.
    Thompson LH; Grealish S; Kirik D; Björklund A
    Eur J Neurosci; 2009 Aug; 30(4):625-38. PubMed ID: 19674082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease.
    Herzog CD; Brown L; Gammon D; Kruegel B; Lin R; Wilson A; Bolton A; Printz M; Gasmi M; Bishop KM; Kordower JH; Bartus RT
    Neurosurgery; 2009 Apr; 64(4):602-12; discussion 612-3. PubMed ID: 19349823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.